What is the prevalence of Ehlers Danlos?

The prevalence of Ehlers-Danlos syndromes (EDS) is estimated to range from 1 in 2,500 to 1 in 5,000 individuals globally, though these figures vary significantly by subtype and are likely underestimates due to historical underdiagnosis.

Understanding Prevalence and Incidence

Because there are 13 distinct subtypes of Ehlers-Danlos, calculating a single incidence rate is challenging. While the Hypermobile type (hEDS) is considered the most common—potentially affecting 1 in 5,000 people—other forms, such as the Classical-like or Vascular types, are significantly rarer. Incidence is difficult to track because many individuals remain undiagnosed for years, often labeled with separate, unrelated symptoms before a systemic Ehlers-Danlos diagnosis is reached.

Demographics and Onset

Ehlers-Danlos syndromes affect all genders, ethnicities, and geographic regions. While some subtypes show a slight female predominance in clinical settings, this may reflect healthcare-seeking behaviors rather than true biological incidence. The condition is lifelong, with symptoms frequently manifesting in childhood or adolescence as joint hypermobility, skin fragility, or chronic pain, though many patients do not receive a formal diagnosis until adulthood.

The Challenge of Data

Accurate epidemiology for Ehlers-Danlos is hindered by the lack of a definitive genetic marker for the most common form (hEDS) and a historical lack of awareness among primary care physicians. Consequently, current clinical data likely represents only a fraction of the true patient population. At DiseaseMaps.org, our community of over 2,500 people with Ehlers-Danlos provides a vital, real-world perspective that complements formal medical literature, highlighting the lived experience of diagnostic delays and the diversity of symptom presentation that often goes uncaptured in traditional registries.

Disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment. Always consult with your physician or a genetic counselor regarding your specific health concerns.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• The Ehlers-Danlos Society: International Classification and Clinical Data